Summary of Endocyte, Inc. (NASDAQ:ECYT) Ratings as of May 16, 2018

May 16, 2018 - By Charla Downs

During Q4 2017 the big money sentiment increased to 1.36. That’s change of 1.04, from 2017Q3’s 0.32. 11 investors sold all, 14 reduced holdings as Endocyte, Inc. ratio increased. 15 grew positions while 19 funds amassed positions. Funds hold 19.91 million shares thus 140.76% more from 2017Q3’s 8.27 million shares.
Meeder Asset holds 0% or 235 shs in its capital. Architects Inc reported 525 shs stake. D E Shaw Communications stated it has 0.01% of its capital in Endocyte, Inc. (NASDAQ:ECYT). 1,400 are owned by Wells Fargo And Mn. Alpine Global Management Limited Liability Corporation reported 0.03% in Endocyte, Inc. (NASDAQ:ECYT). Spark Investment Management Limited Liability Co has invested 0.01% in Endocyte, Inc. (NASDAQ:ECYT). Axa holds 0% of its capital in Endocyte, Inc. (NASDAQ:ECYT) for 23,500 shs. Eam Ltd Liability Com accumulated 98,034 shs. Blackrock Inc stated it has 1.14M shs. Geode Mgmt Limited Liability has 241,498 shs for 0% of their capital. Adage Cap Prtn Group Limited Liability Com has 122,000 shs for 0% of their capital. Virtu Fincl Ltd Company, New York-based fund reported 16,824 shs. The California-based Leisure Mngmt has invested 0.1% in Endocyte, Inc. (NASDAQ:ECYT). Tower Limited Liability (Trc) holds 0% of its capital in Endocyte, Inc. (NASDAQ:ECYT) for 910 shs. Fmr Ltd Liability Corp invested 0% in Endocyte, Inc. (NASDAQ:ECYT).

Endocyte, Inc. had 1 sale and 0 buys since March 9, 2018. This’s net activity of $45,677.

Endocyte, Inc. (NASDAQ:ECYT) Ratings Coverage

Total analysts of 3 have positions in Endocyte (NASDAQ:ECYT) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since February 27, 2018 according to StockzIntelligence Inc Endocyte has 3 analyst reports. The stock rating was upgraded by Cowen & Co to “Outperform” on Tuesday, February 27. Listed here are Endocyte, Inc. (NASDAQ:ECYT) PTs and latest ratings.

13/04/2018 Broker: Jefferies Rating: Buy New Target: $17 Initiates Coverage On
09/03/2018 Broker: Wells Fargo Rating: Outperform New Target: $20 Initiates Coverage On
27/02/2018 Broker: Cowen & Co Old Rating: Market Perform New Rating: Outperform Upgrade

The stock increased 5.45% or $0.66 during the last trading session, hitting $12.77.Endocyte, Inc. has volume of 860,613 shares. Since May 16, 2017 ECYT has risen 296.90% and is uptrending. The stock outperformed the S&P 500 by 285.35%.

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States.The firm is valued at $880.74 million. The firm uses its technology to create novel small molecule drug conjugates and companion imaging agents.Currently it has negative earnings. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.

A couple more Endocyte, Inc. (NASDAQ:ECYT) news were posted by: Seekingalpha.com which released on May 09, 2018 “Endocyte’s (ECYT) CEO Mike Sherman on Q1 2018 Results – Earnings Call Transcript”, also Globenewswire.com on May 09, 2018 posted “Endocyte Provides First Quarter 2018 Financial Results and Operational Update”, the next Globenewswire.com is “Endocyte Announces First Quarter 2018 Earnings Call” on May 02, 2018. Benzinga.com has article titled “26 Stocks Moving In Monday’s Pre-Market Session”.

Endocyte, Inc. (NASDAQ:ECYT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.